Evidence map›Paper›PMID 31933809›Full record

ArticleInternational journal of clinical and experimental pathology2019

Serum lncRNA-UFC1 as a potential biomarker for diagnosis and prognosis of pancreatic cancer.

Peng Liu, Quan-Quan Sun, Tong-Xin Liu, Ke Lu, Na Zhang, Yuan Zhu, Ming Chen

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Peng LiuThe Second Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China.
Quan-Quan SunDepartment of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Tong-Xin LiuDepartment of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Ke LuDepartment of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Na ZhangDepartment of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Yuan ZhuDepartment of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital Hangzhou, Zhejiang Province, China.
Ming ChenThe Second Affiliated Hospital of Soochow University Suzhou, Jiangsu Province, China.
Zhejiang Cancer Hospital · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early diagnosis is important to improve the prognosis of pancreatic cancer (PC). Identifying potential biomarkers is essential for the monitoring and treatment of PC. The long noncoding RNA (lncRNA) UFC1 has been identified as an oncogenic factor in many cancers. However, the expression of UFC1 and its potential role in diagnosis and prognosis of PC remain largely unknown. The present study aimed to investigate the role of serum UFC1 in diagnosis and prognosis. The results indicated that serum UFC1 expression was relatively higher in PC patients than that in healthy volunteers. ROC curve analysis revealed that the serum UFC1 levels could distinguish PC patients from healthy controls, with an AUC value of 0.810. In addition, the serum UFC1 expression level was associated with lymph nodes metastasis, distant metastasis, and clinical stage. Kaplan-Meier analysis indicated that patients with high UFC1 expression exhibited shorter progression-free survival (PFS) and overall survival (OS) than those with low UFC1 expression. Multivariate analysis demonstrated that clinical stage and UFC1 expression level were significant, independent prognostic factors in PC patients. Our data demonstrate that serum UFC1 might serve as a potential biomarker for diagnosis and prognosis of PC.

Indexed as

biomarkerlong noncoding RNAPancreatic cancer

Identifiers

PMID31933809
PMCPMC6949777
OpenAlexW3010173552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.